Oxford and Newcastle, UK – 7 April 2014 – e-Therapeutics plc (AIM: ETX) announces today that Steve Medlicott has joined the Company as Finance Director.
Mr Medlicott joins e-Therapeutics’ management team having previously advised the Company in its £40m fundraising in 2013. He is a Chartered Accountant, trained with PwC, and has previously taken the role of Director responsible for Finance at Waste2Tricity. Mr Medlicott held key business development and sell-side analyst roles with Peel Hunt, N+1 Singer, Altium Capital and Williams de Broe. He was voted the top Industrials analyst in the Thomson Reuters Extel survey numerous times, and was the top Pan-European Industrials analyst in the 2011 Reuters Starmine Awards. He co-founded Blueprint Advisors in 2012.
Commenting on Mr Medlicott’s appointment, Professor Malcolm Young, Chief Executive of e-Therapeutics, said: “We are excited to welcome Steve to the Company as our Finance Director. He has unsurpassed knowledge and understanding of the financial markets and of e-Therapeutics, having supported us to raise funds in 2013. His capabilities and experience will be very valuable to us.”
Mr Medlicott added: "I am extremely pleased to be joining e-Therapeutics. It is a company I have known and worked with for a number of years. As a world leader in network analysis, with its specific application to the pharmacology industry, I join at a tremendously exciting point in its development. I look forward to working with the team to deliver substantial long-term shareholder value."
e-Therapeutics confirms that Steven (Steve) Medlicott is currently a director of Blueprint Advisors Limited, Frenchay Interests Limited and Waste2Tricity Limited, and that there are no other disclosures to be made.
Notes To Editors
e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is focused in cancer and disorders of the nervous system.
e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.
Issued for and on behalf of e-Therapeutics by Instinctif Partners.
To contact the e-Therapeutics team at Instinctif Partners, email e-Therapeutics@instinctif.com
Melanie Toyne-SewellManaging Partner